Novel compound as UCHL-5 inhibitor and uses thereof
Novel pyrazine and quinoxaline derivatives target UCHL-5 to overcome bortezomib resistance, inducing endoplasmic reticulum stress and apoptosis in cancer cells, providing effective treatment for bortezomib-resistant multiple myeloma and colon cancer.
WO2026024060A1 Publication Date: 2026-01-29KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY +1
4 Cites 0 Cited by
Patent Information
- Application Number
- PCT/KR2025/010814
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-21
- Filing Date
- 2025-07-22
- Publication Date
- 2026-01-29
AI Technical Summary
Technical Problem
Existing proteasome inhibitors like bortezomib face challenges with membrane impermeability and cancer cell resistance, limiting their therapeutic efficacy against UCHL-5 mediated diseases such as multiple myeloma and other cancers.
Method used
Development of novel pyrazine and quinoxaline derivative compounds that inhibit UCHL-5 activity, leading to ubiquitinated protein accumulation and endoplasmic reticulum stress in cancer cells, effectively targeting bortezomib-resistant cancers.
Benefits of technology
The compounds induce apoptosis in cancer cells by inhibiting UCHL-5, demonstrating anticancer activity even in bortezomib-resistant cancers, including multiple myeloma and colon cancer, and inhibit ubiquitin-proteasome system activity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a novel compound as an ubiquitin C-terminal hydrolase L5 (UCHL -5) inhibitor and uses thereof.
Need to check novelty before this filing date? Find Prior Art